{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:26:47Z","timestamp":1777271207429,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract\n<\/jats:title>\n          <jats:sec>\n            <jats:title>Background\n<\/jats:title>\n            <jats:p>Atrial fibrillation causes one-fifth of ischaemic strokes, with a high risk of early recurrence. Although long-term anticoagulation is highly effective for stroke prevention in atrial fibrillation, initiation after stroke can be delayed by concerns over intracranial haemorrhage risk. Direct oral anticoagulants offer a significantly lower risk of intracranial haemorrhage than other anticoagulants, potentially allowing earlier anticoagulation and prevention of ischaemic stroke recurrence, but the safety and efficacy of this approach has not been established. This article describes the statistical analysis plan for the OPTIMAS trial as an update to the published protocol. It was written prior to the end of patient follow-up, before database lock and thus while the outcome of the trial is still unknown.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>The optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS) trial will investigate whether early treatment with a direct oral anticoagulant within 4\u00a0days of stroke onset is as effective as, or better than, delayed initiation at 7 to 14\u00a0days from onset.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and design<\/jats:title>\n            <jats:p>OPTIMAS is a multicentre randomised controlled trial with blinded outcome adjudication. Participants with acute ischaemic stroke and atrial fibrillation eligible for anticoagulation with a direct oral anticoagulant are randomised 1:1 to early or delayed initiation. Here, we describe in detail the statistical aspects of OPTIMAS, including outcome measures, sample size calculation, general analysis principles, descriptive statistics, statistical models, and planned subgroup analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Study outcomes<\/jats:title>\n            <jats:p>The primary outcome is a composite of recurrent stroke (ischaemic stroke or symptomatic intracranial haemorrhage) and systemic arterial embolism within 90\u00a0days. Secondary outcomes include each individual component of the composite outcome, major bleeding, functional status assessed by the modified Rankin Scale, ongoing anticoagulation, quality of life, health and social care resource use, and length of hospital stay.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>OPTIMAS aims to provide high-quality evidence on the safety and efficacy of early direct oral anticoagulant initiation after atrial fibrillation-associated acute ischaemic stroke.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registrations<\/jats:title>\n            <jats:p>ISRCTN: 17,896,007; ClinicalTrials.gov: NCT03759938.\u00a0Registered on November 30 2018.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13063-025-08761-6","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T02:56:52Z","timestamp":1739933812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): statistical analysis plan for a randomised controlled trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8798-5217","authenticated-orcid":false,"given":"Norin","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakim-Moulay","family":"Dehbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Freemantle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Best","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip S.","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James K.","family":"Ruffle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Doig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Werring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"1","key":"8761_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25917","volume":"89","author":"TR Meinel","year":"2021","unstructured":"Meinel TR, Branca M, De Marchis GM, Nedeltchev K, Kahles T, Bonati L, et al. Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation. Ann Neurol. 2021;89(1):42\u201353.","journal-title":"Ann Neurol"},{"issue":"4","key":"8761_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1474-4422(24)00037-1","volume":"23","author":"DJ Seiffge","year":"2024","unstructured":"Seiffge DJ, Cancelloni V, R\u00e4ber L, Paciaroni M, Metzner A, Kirchhof P, et al. Secondary stroke prevention in people with atrial fibrillation: treatments and trials. Lancet Neurol. 2024;23(4):404\u201317.","journal-title":"Lancet Neurol"},{"issue":"4","key":"8761_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1474-4422(15)70027-X","volume":"14","author":"LA Sposato","year":"2015","unstructured":"Sposato LA, Cipriano LE, Saposnik G, Ru\u00edz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14(4):377\u201387.","journal-title":"Lancet Neurol"},{"issue":"9921","key":"8761_CR4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet Lond Engl. 2014;383(9921):955\u201362.","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"8761_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/jnnp-2020-325249","volume":"93","author":"JG Best","year":"2022","unstructured":"Best JG, Cardus B, Klijn CJM, Lip G, Seiffge DJ, Smith EE, et al. Antithrombotic dilemmas in stroke medicine: new data, unsolved challenges. J Neurol Neurosurg Psychiatry. 2022;93(9):939\u201351.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"8761_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1474-4422(18)30356-9","volume":"18","author":"DJ Seiffge","year":"2019","unstructured":"Seiffge DJ, Werring DJ, Paciaroni M, Dawson J, Warach S, Milling TJ, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019;18(1):117\u201326.","journal-title":"Lancet Neurol"},{"issue":"11","key":"8761_CR7","first-page":"1609","volume":"18","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2016;18(11):1609\u201378.","journal-title":"Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol"},{"issue":"12","key":"8761_CR8","doi-asserted-by":"publisher","first-page":"e007034","DOI":"10.1161\/JAHA.117.007034","volume":"6","author":"M Paciaroni","year":"2017","unstructured":"Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C, et al. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. J Am Heart Assoc. 2017;6(12):e007034.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"8761_CR9","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1212\/WNL.0000000000008881","volume":"94","author":"JP Appleton","year":"2020","unstructured":"Appleton JP, Woodhouse LJ, Adami A, Becker JL, Berge E, Cala LA, et al. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke. Neurology. 2020;94(5):e439\u201352.","journal-title":"Neurology"},{"issue":"21","key":"8761_CR10","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1212\/WNL.0b013e3181c34a7d","volume":"73","author":"SM Gregoire","year":"2009","unstructured":"Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, J\u00e4ger HR, et al. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology. 2009;73(21):1759\u201366.","journal-title":"Neurology"},{"issue":"8","key":"8761_CR11","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1161\/STROKEAHA.115.008891","volume":"46","author":"M Paciaroni","year":"2015","unstructured":"Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, et al. Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. Stroke. 2015;46(8):2175\u201382.","journal-title":"Stroke"},{"issue":"2","key":"8761_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351\u20136.","journal-title":"AJR Am J Roentgenol."},{"issue":"12","key":"8761_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857\u201367.","journal-title":"Ann Intern Med"},{"issue":"14","key":"8761_CR14","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.122.060666","volume":"146","author":"J Oldgren","year":"2022","unstructured":"Oldgren J, \u00c5sberg S, Hijazi Z, Wester P, Bertilsson M, Norrving B, et al. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation. 2022;146(14):1056\u201366.","journal-title":"Circulation"},{"issue":"5","key":"8761_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1177\/17474930211057722","volume":"17","author":"JG Best","year":"2022","unstructured":"Best JG, Arram L, Ahmed N, Balogun M, Bennett K, Bordea E, et al. Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial. Int J Stroke Off J Int Stroke Soc. 2022;17(5):583\u20139.","journal-title":"Int J Stroke Off J Int Stroke Soc"},{"key":"8761_CR16","first-page":"239698732211060","volume":"15","author":"U Fischer","year":"2022","unstructured":"Fischer U, Trelle S, Branca M, Salanti G, Paciaroni M, Ferrari C, et al. Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): Protocol for an international, multicentre, randomised-controlled, two-arm, open, assessor-blinded trial. Eur Stroke J. 2022;15:23969873221106044.","journal-title":"Eur Stroke J"},{"issue":"4","key":"8761_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/2396987318787124","volume":"3","author":"D Munn","year":"2018","unstructured":"Munn D, Abdul-Rahim AH, Fischer U, Werring DJ, Robinson TG, Dawson J. A survey of opinion: When to start oral anticoagulants in patients with acute ischaemic stroke and atrial fibrillation? Eur Stroke J. 2018;3(4):355\u201360.","journal-title":"Eur Stroke J"},{"issue":"1","key":"8761_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/17474930221106014","volume":"18","author":"JG Best","year":"2023","unstructured":"Best JG, Jesuthasan A, Werring DJ. Cerebral small vessel disease and intracranial bleeding risk: Prognostic and practical significance. Int J Stroke. 2023;18(1):44\u201352.","journal-title":"Int J Stroke"},{"issue":"8","key":"8761_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","volume":"12","author":"JM Wardlaw","year":"2013","unstructured":"Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822\u201338.","journal-title":"Lancet Neurol"},{"issue":"3\u20134","key":"8761_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000375153","volume":"39","author":"GM Potter","year":"2015","unstructured":"Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. Cerebrovasc Dis Basel Switz. 2015;39(3\u20134):224\u201331.","journal-title":"Cerebrovasc Dis Basel Switz"},{"issue":"5","key":"8761_CR21","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1161\/STROKEAHA.121.036695","volume":"53","author":"S Kimura","year":"2022","unstructured":"Kimura S, Toyoda K, Yoshimura S, Minematsu K, Yasaka M, Paciaroni M, et al. Practical \u201c1-2-3-4-Day\u201d Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. Stroke. 2022;53(5):1540\u20139.","journal-title":"Stroke"},{"issue":"12","key":"8761_CR22","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/jnnp.53.12.1080","volume":"53","author":"JC van Swieten","year":"1990","unstructured":"van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J. Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry. 1990;53(12):1080\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08761-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08761-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08761-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T02:56:54Z","timestamp":1739933814000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08761-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8761"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08761-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study has been approved and is overseen by the National Research Ethics Service Committee (South Central\u2014Oxford B Research Ethics Committee, 19\/SC\/0021 (all nations), 14 March 2019). For Scotland, Scotland A Research Ethics Committee, 20\/SS\/0069, 18th August 2020). We have obtained informed consent from all participants in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}